ConductScience.org, home

Paper36915460

Using a combination of fruquintinib, raltitrexed, and S-1 as a third-line treatment for metastatic colorectal cancer with co-existence of Hodgkin lymphoma: a case report.

Wan Y and 1 other. J Gastrointest Oncol, 2023. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Using a combination of fruquintinib, raltitrexed, and S-1 as a third-line treatment for metastatic colorectal cancer with co-existence of Hodgkin lymphoma: a case report. Papers, record 36915460. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36915460

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Using a combination of fruquintinib, raltitrexed, and S-1 as a third-line treatment for metastatic colorectal cancer with co-existence of Hodgkin lymphoma: a case report.
PubMed
Journal
J Gastrointest Oncol
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
2
iCite
Relative citation ratio, by iCite
0.16
iCite
Revised in PubMed
2023-03-15
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wan YYuming
2Luo DDeyun

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References17

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126938715Novel anti-angiogenic therapeutic strategies in colorectal cancer.Expert Opin Investig Drugs2016https://conductscience.org/library/papers/26938715PubMed
235261903Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review.Transl Cancer Res2022https://conductscience.org/library/papers/35261903PubMed
335557597Efficacy and safety of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer: a retrospective cohort study.J Gastrointest Oncol2022https://conductscience.org/library/papers/35557597PubMed
436530921Biomarkers in the development of individualized treatment regimens for colorectal cancer.Front Med (Lausanne)2022https://conductscience.org/library/papers/36530921PubMed
536307056Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.Ann Oncol2023https://conductscience.org/library/papers/36307056PubMed
634109130Combination of Anti-EGFR and Anti-VEGF Drugs for the Treatment of Previously Treated Metastatic Colorectal Cancer: A Case Report and Literature Review.Front Oncol2021https://conductscience.org/library/papers/34109130PubMed
731790382Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials.Med Sci Monit2019https://conductscience.org/library/papers/31790382PubMed
831496821Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer.Cancer Manag Res2019https://conductscience.org/library/papers/31496821PubMed
919114685A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.J Clin Oncol2009https://conductscience.org/library/papers/19114685PubMed
1031848739Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?Int J Colorectal Dis2020https://conductscience.org/library/papers/31848739PubMed
1129946728Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.JAMA2018https://conductscience.org/library/papers/29946728PubMed
1217876013Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.J Clin Oncol2007https://conductscience.org/library/papers/17876013PubMed
1320530421Chronic exposure of colorectal cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-FU resistance.Anticancer Res2010https://conductscience.org/library/papers/20530421PubMed
1423313143The upregulation of dihydropyrimidine dehydrogenase in liver is involved in acquired resistance to 5-fluorouracil.Eur J Cancer2013https://conductscience.org/library/papers/23313143PubMed
1530651398S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial.Oncologist2019https://conductscience.org/library/papers/30651398PubMed
1633830591Bevacizumab Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study.Oncologist2021https://conductscience.org/library/papers/33830591PubMed
1719196673Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.N Engl J Med2009https://conductscience.org/library/papers/19196673PubMed

Download CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
39352649Clinical research progress of fruquintinib in the treatment of malignant tumors.Invest New Drugs2024https://conductscience.org/library/papers/39352649PubMed
38756629Efficacy and safety of gemcitabine plus raltitrexed or S-1 versus standard third-line therapies in metastatic colorectal cancer: a retrospective cohort study.J Gastrointest Oncol2024https://conductscience.org/library/papers/38756629PubMed

Download CSV of cited by

Genes19

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
CXCL1310563PubTator's text mininghttps://conductscience.org/library/genes/10563NCBI Gene
DPYD1806PubTator's text mininghttps://conductscience.org/library/genes/1806NCBI Gene
FUT42526PubTator's text mininghttps://conductscience.org/library/genes/2526NCBI Gene
KDR3791PubTator's text mininghttps://conductscience.org/library/genes/3791NCBI Gene
KRT2054474PubTator's text mininghttps://conductscience.org/library/genes/54474NCBI Gene
MLH14292PubTator's text mininghttps://conductscience.org/library/genes/4292NCBI Gene
MSH24436PubTator's text mininghttps://conductscience.org/library/genes/4436NCBI Gene
MSH62956PubTator's text mininghttps://conductscience.org/library/genes/2956NCBI Gene
PAX55079PubTator's text mininghttps://conductscience.org/library/genes/5079NCBI Gene
PIK3CA5290PubTator's text mininghttps://conductscience.org/library/genes/5290NCBI Gene
PMS25395PubTator's text mininghttps://conductscience.org/library/genes/5395NCBI Gene
PWWP3A84939PubTator's text mininghttps://conductscience.org/library/genes/84939NCBI Gene
TNFRSF8943PubTator's text mininghttps://conductscience.org/library/genes/943NCBI Gene
TRBV20OR9-26962PubTator's text mininghttps://conductscience.org/library/genes/6962NCBI Gene
TYMS7298PubTator's text mininghttps://conductscience.org/library/genes/7298NCBI Gene
VEGFA7422PubTator's text mininghttps://conductscience.org/library/genes/7422NCBI Gene
VEGFC7424PubTator's text mininghttps://conductscience.org/library/genes/7424NCBI Gene
ZHX222882PubTator's text mininghttps://conductscience.org/library/genes/22882NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36915460

GET https://conductscience.org/api/papers/v1/36915460/authors